Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Orbimed Advisors10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 25/10/23 | 25/10/27 | 1,000,000 sh | $1.52 | $1,520,000 | −16.7% |
OrbiMed Capital GP V10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 25/10/23 | 25/10/27 | 1,000,000 sh | $1.52 | $1,520,000 | −16.7% |
Orbimed Advisors10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 25/09/10 | 25/09/12 | 500,000 sh | $1.80 | $900,000 | −7.7% |
OrbiMed Capital GP V10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 25/09/10 | 25/09/12 | 500,000 sh | $1.80 | $900,000 | −7.7% |
David Henry MackPresident and CEO | PMV PharmaceuticalsPMVP | Open-market sale | 25/07/01 | 25/07/03 | 58,411 sh | $1.06 | $61,915.66 | −9.8% |
Robert TicktinGeneral Counsel & COO | PMV PharmaceuticalsPMVP | Open-market sale | 25/07/01 | 25/07/03 | 23,151 sh | $1.06 | $24,540.06 | −19.0% |
Deepika JalotaChief Development Officer | PMV PharmaceuticalsPMVP | Open-market sale | 25/07/01 | 25/07/03 | 33,065 sh | $1.06 | $35,048.9 | −26.9% |
PMV PharmaceuticalsPMVP | Open-market sale | 25/07/01 | 25/07/03 | 28,249 sh | $1.06 | $29,943.94 | −32.0% | |
Deepika JalotaChief Development Officer | PMV PharmaceuticalsPMVP | Open-market sale | 24/09/11 | 24/09/12 | 7,218 sh | $1.50 | $10,827 | −5.8% |
PMV PharmaceuticalsPMVP | Open-market sale | 24/09/11 | 24/09/12 | 2,891 sh | $1.50 | $4,336.5 | −3.2% | |
Orbimed Advisors10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 23/11/22 | 23/11/24 | 87,786 sh | $2.23 | $195,762.78 | −100.0% |
OrbiMed Capital GP V10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 23/11/22 | 23/11/24 | 87,786 sh | $2.23 | $195,762.78 | −100.0% |
OrbiMed Genesis GP10% Owner | PMV PharmaceuticalsPMVP | Open-market sale | 23/11/22 | 23/11/24 | 87,786 sh | $2.23 | $195,762.78 | −100.0% |
Deepika JalotaChief Development Officer | PMV PharmaceuticalsPMVP | Open-market sale | 23/09/15 | 23/09/18 | 4,104 sh | $6.62 | $27,168.48 | −12.1% |
Leila AllandChief Medical Officer | PMV PharmaceuticalsPMVP | Open-market sale | 23/09/15 | 23/09/18 | 6,291 sh | $6.62 | $41,646.42 | −12.1% |